Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
公司代码MRVI
公司名称Maravai LifeSciences Holdings Inc
上市日期Nov 20, 2020
CEOBrust (Bernd)
员工数量570
证券类型Ordinary Share
年结日Nov 20
公司地址10770 Wateridge Circle Suite 200
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92121
电话18585460004
网址https://www.maravai.com/
公司代码MRVI
上市日期Nov 20, 2020
CEOBrust (Bernd)